DORA-22 manufacturers
- DORA-22
-
- $133.00
-
2026-05-11
- CAS:1088991-95-0
- Purity: 99.73%
- Supply Ability: 10g
|
| | DORA-22 Basic information |
| Product Name: | DORA-22 | | Synonyms: | DORA-22;[(2R,5R)-5-[(5-FLUOROPYRIDIN-2-YL)OXYMETHYL]-2-METHYLPIPERIDIN-1-YL]-(5-FLUORO-2-PYRIMIDIN-2-YLPHENYL)METHANONE;DORA 22,DORA22;Methanone, [(2R,5R)-5-[[(5-fluoro-2-pyridinyl)oxy]methyl]-2-methyl-1-piperidinyl][5-fluoro-2-(2-pyrimidinyl)phenyl]-;DORA-22, 10 mM in DMSO | | CAS: | 1088991-95-0 | | MF: | C23H22F2N4O2 | | MW: | 424.44 | | EINECS: | | | Product Categories: | | | Mol File: | 1088991-95-0.mol |  |
| | DORA-22 Chemical Properties |
| Boiling point | 524.3±50.0 °C(Predicted) | | density | 1.258±0.06 g/cm3(Predicted) | | pka | 1.54±0.22(Predicted) |
| | DORA-22 Usage And Synthesis |
| Description | DORA-22 is an orexin receptor antagonist. | | Uses | DORA-22 is an orally active dual orexinergic receptor antagonist, and improves the sleep disruption and memory impairment. DORA-22 can be used for study of insomnia[1][2]. | | References | [1] Gamble MC, et al. The dual orexinergic receptor antagonist DORA-22 improves the sleep disruption and memory impairment produced by a rodent insomnia model. Sleep. 2020;43(3):zsz241. DOI:10.1093/sleep/zsz241
[2] Lin Y, Ret al. Positive allosteric adenosine A2A receptor modulation suppresses insomnia associated with mania- and schizophrenia-like behaviors in mice. Front Pharmacol. 2023;14:1138666. Published 2023 Apr 19. DOI:10.3389/fphar.2023.1138666 |
| | DORA-22 Preparation Products And Raw materials |
|